- $438.66m
- $445.98m
- $99.99m
Brief: Neuropace Completes Enrollment In Feasibility Study Of Rns System
Neuropace Inc reports results for the quarter ended September 30 - Earnings Summary
Neuropace Inc expected to post a loss of 27 cents a share - Earnings Preview
Neuropace Inc reports results for the quarter ended in June - Earnings Summary
Neuropace Inc expected to post a loss of 30 cents a share - Earnings Preview
Neuropace Inc expected to post a loss of 32 cents a share - Earnings Preview
Neuropace Inc reports results for the quarter ended in December - Earnings Summary
Neuropace Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Neuropace Announces Preliminary Unaudited Revenue For Q4 And FY2023
Brief: NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
Brief: Neuropace Inc Entered Into Agreement With Rapport Therapeutics
Brief: NeuroPace, Inc. Q3 revenue USD 16.427 million
Brief: Neuropace Announces Rns System Enhancements Designed To Streamline Care
Neuropace Inc reports results for the quarter ended in June - Earnings Summary
Brief: NeuroPace, Inc. Q2 revenue USD 16.51 million
Brief: Neuropace Announces CEO Transition
Musk's Neuralink valued at about $5 bln despite long road to market
Neuropace Inc reports results for the quarter ended in March - Earnings Summary
Neuropace Inc expected to post a loss of 46 cents a share - Earnings Preview